CLINICAL TRIALS PROFILE FOR SAGE-217

Clinical Trials for SAGE-217

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02978326 ↗	A Study to Evaluate SAGE-217 in Subjects With Severe Postpartum Depression	Completed	Sage Therapeutics	Phase 3	This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the efficacy, safety and pharmacokinetics of SAGE-217 in approximately 140 adult female subjects diagnosed with severe postpartum depression.
NCT02978781 ↗	A Study to Evaluate SAGE-217 in Participants With Essential Tremor	Completed	Sage Therapeutics	Phase 2	This study is a three-part, multicenter, Phase 2a study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of SAGE-217 in adult participants with essential tremor.
NCT03000530 ↗	A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder	Completed	Sage Therapeutics	Phase 2	This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with moderate to severe Major Depressive Disorder.
NCT03000569 ↗	A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease	Completed	Sage Therapeutics	Phase 2	This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29 participants with moderate to severe Parkinson's Disease.
NCT03284931 ↗	A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model	Completed	Sage Therapeutics	Phase 1	This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.

Clinical Trial Conditions for SAGE-217

Condition Name

Condition Name
Intervention	Trials
Major Depressive Disorder	5
Depressive Disorder, Major	2
Major Depressive Episode	1
Parkinson Disease	1

Condition MeSH

Condition MeSH
Intervention	Trials
Depression	11
Depressive Disorder	11
Depressive Disorder, Major	9
Disease	8

Clinical Trial Locations for SAGE-217

Trials by Country

Trials by Country
Location	Trials
United States	199
United Kingdom	5
Spain	1

Trials by US State

Trials by US State
Location	Trials
Texas	12
Georgia	12
Florida	12
California	12
New Jersey	10

Clinical Trial Progress for SAGE-217

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	8
Phase 2	4
Phase 1	2

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	8
Recruiting	3
Terminated	2

Clinical Trial Sponsors for SAGE-217

Sponsor Name

Sponsor Name
Sponsor	Trials
Sage Therapeutics	14

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	14